Seven Eight Capital, LP Zai Lab LTD Transaction History

Seven Eight Capital, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$27.77 - $64.4 $122,437 - $283,939	-4,409 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$54.9 - $105.21 $179,303 - $343,615	-3,266 Reduced 42.55%	4,409 $277,000
Q3 2021 Nov 15, 2021	BUY	$105.0 - $178.37 $805,875 - $1.37 Million	7,675 New	7,675 $809,000
Q3 2020 Nov 16, 2020	SELL	$73.3 - $89.48 $197,910 - $241,596	-2,700 Closed	0 $0
Q2 2020 Aug 06, 2020	BUY	$48.82 - $82.53 $131,814 - $222,831	2,700 New	2,700 $222,000

123

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.55B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.